D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
LXRX holding history
Lexicon Pharmaceuticals, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
LXRX overviewAll 13F holders of LXRXFull Q2 2026 holdings
- Shares (Q2 2026)
- 22,200
- Value
- $53.3K
- % of portfolio
- <0.1%
- Quarters held
- 14
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 22,200 | $53.3K | <0.1% | +22,200 | New | Holders |
| Q3 2025 | 0 | $0 | 0.0% | −23,723−100.0% | Sold out | Holders |
| Q2 2025 | 23,723 | $22.4K | <0.1% | +23,723 | New | Holders |
| Q1 2024 | 0 | $0 | 0.0% | −359,210−100.0% | Sold out | Holders |
| Q4 2023 | 359,210 | $549.6K | <0.1% | −424,912−54.2% | Reduced | Holders |
| Q3 2023 | 784,122 | $854.7K | <0.1% | −429,604−35.4% | Reduced | Holders |
| Q2 2023 | 1,213,726 | $2.78M | <0.1% | −1,727,271−58.7% | Reduced | Holders |
| Q1 2023 | 2,940,997 | $7.15M | <0.1% | −136,976−4.5% | Reduced | Holders |
| Q4 2022 | 3,077,973 | $5.88M | <0.1% | +33,996+1.1% | Added | Holders |
| Q3 2022 | 3,043,977 | $7.31M | <0.1% | −184,095−5.7% | Reduced | Holders |
| Q2 2022 | 3,228,072 | $6.00M | <0.1% | −6320.0% | Reduced | Holders |
| Q1 2022 | 3,228,704 | $6.75M | <0.1% | +420,276+15.0% | Added | Holders |
| Q4 2021 | 2,808,428 | $11.1M | <0.1% | −407,620−12.7% | Reduced | Holders |
| Q3 2021 | 3,216,048 | $15.5M | <0.1% | −186,377−5.5% | Reduced | Holders |
| Q2 2021 | 3,402,425 | $15.6M | <0.1% | +395,813+13.2% | Added | Holders |
| Q1 2021 | 3,006,612 | $17.6M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.